Blockchain Registration Transaction Record

Recce Pharmaceuticals Administers Highest Dose in Phase I/II UTI Urosepsis Trial

Recce Pharmaceuticals administers the highest dose in the Phase I/II UTI Urosepsis trial, marking a significant milestone in the development of R327 for the treatment of serious bacterial infections.

The progress in Recce Pharmaceuticals' clinical trial for UTI and urosepsis treatment signifies a potential breakthrough in combating serious bacterial infections, including superbug forms. The successful administration of the highest dosage of R327 in the trial to date is a significant milestone, with potential regulatory implications. This development holds promise for the future of intravenous and topical therapies in the treatment of bacterial infections, highlighting the importance of ongoing research and innovation in the pharmaceutical industry.